Compare · BNTX vs NBIX
BNTX vs NBIX
Side-by-side comparison of BioNTech SE (BNTX) and Neurocrine Biosciences Inc. (NBIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and NBIX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $23.93B, about 1.6x NBIX ($14.58B).
- Both names hit the wire about 15 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Neurocrine Biosciences Inc.
- Price
- -
- -
- Market cap
- $23.93B
- $14.58B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 1996
- News (4w)
- 15
- 15
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Latest BNTX
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,860,757 worth of Ordinary Shares (79,000 units at $99.50) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 410,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,239,071 worth of Ordinary Shares (64,000 units at $97.49) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 489,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
Latest NBIX
- SEC Form 3 filed by Neurocrine Biosciences Inc.
- Guggenheim resumed coverage on Neurocrine Biosciences with a new price target
- Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update
- Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
- Chief Scientific Officer Onyia Jude was granted 3,587 shares and covered exercise/tax liability with 1,936 shares, increasing direct ownership by 8% to 22,647 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer Lippoldt Darin was granted 4,483 shares and covered exercise/tax liability with 2,419 shares, increasing direct ownership by 4% to 56,793 units (SEC Form 4) (withholding obligation)
- Chief Medical Officer Keswani Sanjay Chandru was granted 3,914 shares and covered exercise/tax liability with 2,112 shares, increasing direct ownership by 122% to 3,281 units (SEC Form 4) to satisfy tax liability
- Director Gorman Kevin Charles was granted 14,343 shares and covered exercise/tax liability with 7,839 shares, increasing direct ownership by 1% to 517,797 units (SEC Form 4) to cover taxes
- Chief Executive Officer Gano Kyle was granted 8,117 shares and covered exercise/tax liability with 4,380 shares, increasing direct ownership by 2% to 154,728 units (SEC Form 4) (tax withholding)